CRISPR-Cas9 may inadvertently increase cancer risk in treated cells, according to a new study from researchers at Cambridge University and the Karolinska Institutet.
The deal gives Editas Medicine an exclusive ‘first’ to negotiate for licenses to genome-editing inventions that rise from the sponsored research.
Probably not. But there is an increasing demand for people with data and computing skills, and the life sciences sector in California may be losing the battle with Silicon Valley for those people.
Scientists now have easy access to the full power of CRISPR, without any learning curve, thanks to Synthego’s Engineered Cells Portfolio.
The Norwegian Academy of Science and Letters, which is one of the world’s richest science awards in the world, have announced its award will go to three discoverers of the genome-editing tool, CRISPR-Cas9.
U.S. regulators have put a halt on a clinical trial planned to use CRISPR technology on sickle-cell patients due to ‘unspecified questions’, CRISPR Therapeutics said on Wednesday.
Scientists have successfully developed a far easier way to manipulate different genes by using a common research model, baker’s yeast.
A great look at the concerns over DIY Gene Editing in The New York Times.
Researchers have slowed the growth of pancreatic cancer by harnessing CRISPR genome editing to remove key molecules implicated in its spread.